A Phase II Trial of Axicabtagene Ciloleucel with Radiation Therapy in Relapsed/Refractory Follicular Lymphoma
Phase 2
20
about 4.7 years
18+
1 site in TX
Why this study is shown
What this study is about
This trial is testing the safety of axicabtagene ciloleucel, a type of drug, given with radiation therapy to people whose follicular lymphoma has returned or not responded to previous treatments. The goal is to see how safe this combination treatment is.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Acetaminophen
- 2.Take Axicabtagene Ciloleucel
- 3.Take Cyclophosphamide
- +3 more
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
paracetamol (Reduces fever and pain (mechanism not fully understood)), axicabtagene ciloleucel, cyclophosphamide (Alkylating chemotherapy; crosslinks DNA strands), diphenhydramine, Antineoplastic Agent [TC] (Nucleic Acid Synthesis Inhibitors), prednisone
oral, infusion, injection (Injection)
Primary: Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Oncology